Abiopharma

🔍 Mukhija Manavdeep Singh (Director)

Company: Eagle Nuclear Energy Corp. (NUCL)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 250,000 shares of Common Stock, par value $0.0001 per share (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 564,793.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 750,000 shares of Employee Stock Option (right to buy) at $10.0 per share (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 750,000.00 | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: The securities reported in Column 4 of Table I are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Eagle Nuclear Energy Corp. (the "Issuer"), subject to the vesting schedule and other conditions set forth in the applicable RSU award and Issuer's 2025 Equity Incentive Plan. One-third of the RSUs vested upon grant, one-third will vest on the first anniversary of the grant date, and the remaining one-third will vest on the second anniversary of the grant date, in each case subject to the reporting person's continued service with the Issuer.
• F2: Certain of the securities reported in Column 5 are RSUs, each representing a contingent right to receive one share of Common Stock, subject to the terms and conditions of the applicable RSU award agreement, including the vesting schedule set forth therein, and the Issuer's 2025 Equity Incentive Plan.
• F3: The stock options vest as follows: one‑third vested upon grant, one‑third will vest on the first anniversary of the grant date, and the remaining one‑third will vest on the second anniversary of the grant date, in each case subject to the reporting person's continued employment and the terms and conditions of the applicable option award agreement and the Issuer's 2025 Equity Incentive Plan.